Trial Profile

Lerapolturev (Formerly Known as PVSRIPO) With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lerapolturev (Primary) ; Programmed cell death 1 receptor antagonists (Primary)
Indications Malignant melanoma; Skin cancer
Focus Adverse reactions; Therapeutic Use
Acronyms LUMINOS-102
Sponsors Istari Oncology

Most Recent Events

02 Oct 2024 Planned End Date changed from 1 Oct 2024 to 1 Dec 2024.
02 Oct 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Oct 2024.
04 Apr 2024 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com